A5027042419- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Long-Term Effects of COVID-19
- Mechanical Circulatory Support Devices
- Statistical Methods and Inference
- Aortic Disease and Treatment Approaches
- Cardiovascular Function and Risk Factors
- Infective Endocarditis Diagnosis and Management
- Health, Environment, Cognitive Aging
- Advanced Causal Inference Techniques
- Coronary Interventions and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Transplantation: Methods and Outcomes
- Statistical Methods and Bayesian Inference
- Aortic aneurysm repair treatments
- Vaccine Coverage and Hesitancy
- Circular RNAs in diseases
- Hearing Loss and Rehabilitation
- Animal Virus Infections Studies
- Cerebral Palsy and Movement Disorders
- Noise Effects and Management
- Acute Myocardial Infarction Research
- Neonatal and fetal brain pathology
Erasmus MC
2018-2024
University of Thessaly
2024
Erasmus University Rotterdam
2019-2023
University of New Mexico
2023
Erasmus MC Cancer Institute
2023
Evangelismos Hospital
1999
Structured abstract for full paper Background After recovery from COVID-19, most patients have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an inexpensive and widely available treatment COVID-19. Methods The Convalescent-plasma-for-COVID (ConCOVID) study was a randomized trial comparing with standard of care therapy in hospitalized COVID-19 the Netherlands. Patients were 1:1 received 300ml antibody titers at least 1:80. primary endpoint day-60 mortality key...
Abstract In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers neutralizing SARS-CoV-2 antibodies, no overall benefit was observed. Using comprehensive translational approach, we unravel the virological and immunological responses following disentangle which may should be focus future studies. Convalescent is safe, does not improve survival, has effect on disease course, nor enhance viral...
Illness after infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is less compared previous variants. Data on disease burden in immunocompromised patients are lacking. We investigated clinical characteristics and outcomes of 2019 (COVID-19) caused by Omicron.Organ transplant recipients, anti-CD20 therapy, allogenic hematopoietic stem cell transplantation recipients infected were included. Characteristics consenting collected contacted regularly...
In this review, we present an overview of joint models for longitudinal and time-to-event data. We introduce a generalized formulation the model that incorporates multiple outcomes varying types. focus on extensions parametrization association structure links outcomes, estimation techniques, dynamic predictions. also outline software available application these models.
Missing data are a common challenge encountered in research which can compromise the results of statistical inference when not handled appropriately. This paper aims to introduce basic concepts missing non-statistical audience, list and compare some most popular approaches for handling practice provide guidelines recommendations dealing with reporting scientific research. Complete case analysis single imputation simple practice, however, cases they guaranteed valid inferences. Multiple is...
The potential benefit of convalescent plasma (CP) therapy for coronavirus disease 2019 (COVID-19) is highest when administered early after symptom onset. Our objective was to determine the effectiveness CP in improving course COVID-19 among high-risk outpatients.A multicentre, double-blind randomized trial conducted comparing 300 mL with non-CP. Patients were ≥50 years, symptomatic <8 days, had confirmed RT-PCR or antigen test result and at least one risk factor severe COVID-19. primary...
Abstract Background The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. Methods Patients were randomly assigned receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. Results Severe was observed 10 (20%) patients treated with compared 7 8 (88%) the IVIG...
Background and Objectives: A high systemic immune-inflammation index (SIII) at diagnosis of various cancers, including pancreatic cancer, is associated with poor prognosis. The impact FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) chemotherapy or stereotactic body radiotherapy on this unknown. In addition, the prognostic value changes in SIII during treatment unclear. retrospective analysis, we aimed to find answers regarding patients advanced cancer. Methods: Patients...
We quantified changes in the auditory acuity of 675 aging adults (mean age 71.1 years, 52.0% female, mean follow-up 4.4 years ± 0.2) an ongoing cohort study with a pure-tone audiogram and speech-in-noise test. Generalized estimating equation models were used to association between hearing loss progression age, sex, education, cognition, BMI, blood pressure, having type 2 diabetes mellitus, cholesterol ratio, smoking alcohol consumption. The was 0.29 1.35 dB/year (low high frequencies)....
There is no ideal valve substitute for young adults requiring aortic replacement. Multicenter data supporting use of the Ross procedure with respect to long-term postoperative valve-related mortality and reintervention, as well function autograft pulmonary homograft, are needed.To determine clinical echocardiographic outcomes in middle-aged patients undergoing procedure.A retrospective multicenter international cohort study a median follow-up period 9.2 years was conducted 5 experienced...
The aim of this study was to improve insight into male-female differences in patients undergoing ascending aortic aneurysm surgery. Consecutive that underwent surgery between January 1991-December 2016 were retrospectively analyzed. Patient and procedural characteristics, 30-day mortality, survival compared male female patients. Multivariable Cox-regression analysis performed explore factors associated with long-term mortality. Of 631 included patients, 36% They older (66 (55.9-72.9) vs 56...
Abstract Background The COVIH study is a prospective coronavirus disease 2019 (COVID-19) vaccination in 1154 people with HIV (PWH), of whom 14% showed reduced antibody levels after primary vaccination. We evaluated whether an additional boosts immune responses these hyporesponders. Methods end point was the increase antibodies 28 days mRNA-1273 Secondary points included neutralizing antibodies, S-specific T-cell and B-cell responses, reactogenicity. Results Of 66 participants, 40 previously...
Purpose: Evaluation of the treatment malignant obstructive jaundice by percutaneous insertion uncovered stents. Material and Methods: 51 patients (35 men, 16 women) with inoperable biliary obstruction underwent placement Wallstent endoprostheses. A total 65 endoprostheses were inserted. Results: technical success rate was 98%, procedure-related complications 10%. Early within first 30 days 2%. clinical 98% 30-day mortality late 16%. overall stent occlusion 18% at a mean 288.4 days. Mean...
Abstract Background Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations this is unknown. Methods and Findings A prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S Ad26.COV2.S vaccines adult PLWH, without prior COVID-19, compared HIV-negative controls. The primary endpoint was anti-spike IgG response after mRNA vaccination. Secondary endpoints included serological vector vaccination, anti-SARS-CoV-2 T-cell...
Abstract Major Depressive Disorder (MDD) is a debilitating psychiatric disorder that currently affects more than 20% of the adult US population and leading cause disability worldwide. Although treatment with antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), has demonstrated clinical efficacy, inherent complexity heterogeneity disease “trial error” approach in choosing most effective antidepressant for each patient, allows only subset patients to achieve response first...